New understanding of pulmonary hypertension leads to promising drug targets

August 22, 2016, University of Pittsburgh Schools of the Health Sciences

A groundbreaking new study led by researchers from the University of Pittsburgh and UPMC has identified a new group of compounds that could have robust effects in treating pulmonary hypertension (PH), an enigmatic but sometimes fatal disease of the blood vessels of the lungs that currently has no cure. The findings, which were published today in the Journal of Clinical Investigation, highlight the use of these drugs to alter vessel stiffness and its downstream control of metabolism, a link previously unknown for people suffering from the progressive disease.

"If we aim to cure this , the next set of medications and treatments should be those that target the origin at the molecular level," said Stephen Y. Chan, M.D., Ph.D., director of the UPMC Center for Pulmonary Vascular Biology and Medicine at the Vascular Medicine Institute at Pitt, and senior author of the study. "As a community, we are struggling right now to understand those origins of PH, and this study aimed to address that untapped need."

Affecting tens of millions of people worldwide, PH is in the arteries in the lungs, which makes it difficult for blood to flow from the heart to the lungs. Symptoms of the disease, which can lead to heart failure, include shortness of breath, fatigue and chest pain; and, in its early stages, might not be noticeable for months or even years. Often a life-threatening condition, it becomes progressively worse, making early and accurate diagnosis important to allow treatments that extend and improve the quality of life for many patients.

To make these discoveries, Dr. Chan and his colleagues used a comprehensive array of tools derived from cells and tissues of animal and humans with PH. Notably, these findings also were relevant to PH caused by (HIV) infection—a particularly mysterious form of this disease where the underlying molecular processes have remained unknown for decades.

Dr. Chan's team found that stiffening or hardening of the vessels in the lung is an early event in PH that triggers the activation of two critical signaling molecules called YAP and TAZ. These molecules in turn activate a protein called GLS1, which controls how cells in the vessel produce and use energy.

"The link between vessel hardening and energy production is absolutely central to this disease," said Dr. Chan. "That discovery offers us so many new ways to design drugs tailor-made to stop PH in its tracks."

As proof-of-concept, Dr. Chan's team tested both the YAP inhibitor verteporfin, a Food and Drug Administration-approved medication for macular degeneration, and a GLS1 inhibitor called CB-839, which is in clinical trials for cancer. They found that both of these compounds displayed robust effects in improving PH in a rodent model of disease.

"We are very encouraged by these results," said Dr. Chan. "We are working to repurpose these drugs for treatment of human PH, which now can include long-neglected disease types such as HIV-related conditions and others. We hope that we can do so without the delay of decades that often happens when developing new compounds from scratch."

Given that vessel stiffness is prevalent in other diseases—including cancer progression—these results also may be important beyond PH, noted Dr. Chan.

"There is always more work to be done," he said. "But, we feel this represents a significant milestone in our quest to cure this disease."

Explore further: Pulmonary artery stiffening is an early driver of pulmonary hypertension

Related Stories

Pulmonary artery stiffening is an early driver of pulmonary hypertension

June 2, 2016
Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung. Pulmonary hypertension is caused by a variety of factors, ...

Hidden origins of pulmonary hypertension revealed by network modeling

June 24, 2014
In a groundbreaking study, researchers from Brigham and Women's Hospital (BWH) have identified a related family of molecules believed to be a major root cause of pulmonary hypertension, a deadly vascular disease with undefined ...

Blood test shows promise in gauging severity of pulmonary arterial hypertension

June 20, 2016
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high ...

Protein target may block deadly arterial remodeling in pulmonary hypertension

July 5, 2016
Pulmonary hypertension is a highly lethal disease that transforms the thin, flexible vasculature of the lungs into thick, dysfunctional blood vessels that can kill.

Positive results for new oral drug for pulmonary hypertension

December 23, 2015
Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal ...

Recommended for you

Inflammation critical for preventing heart attacks and strokes, study reveals

September 19, 2018
Inflammation, long considered a dangerous contributor to atherosclerosis, actually plays an important role in preventing heart attacks and strokes, new research from the University of Virginia School of Medicine reveals.

Effective drug delivery to heart with tannic acid

September 18, 2018
Typical methods of drug delivery to the heart require surgical procedures involving incisions in the chest wall and bones. To efficiently treat cardiovascular and related vascular diseases without surgery, a KAIST research ...

Daily low-dose aspirin found to have no effect on healthy life span in older people

September 16, 2018
In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living (life free of dementia ...

Financial incentives for cholesterol control may be cost-effective

September 14, 2018
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins (LDL) cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease ...

Apple's smartwatch has a heart monitor now

September 13, 2018
There will soon be another way to monitor your heart—from your wrist.

3-D virtual simulation gets to the 'heart' of irregular heartbeats

September 12, 2018
In a proof of concept study, scientists at Johns Hopkins report they have successfully performed 3-D personalized virtual simulations of the heart to accurately identify where cardiac specialists should electrically destroy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.